Business Wire

STALLERGENES-GREER

Share
FDA Approves U.S. Pediatric Indication Extension for Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, today announced that the U.S Food and Drug Administration (FDA) has approved Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of a peanut allergy. This approval expands the January 2020 FDA approval for patients ages 4-17 years. Palforzia® is to date the first and only approved oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.

Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. Compared with other food allergies, peanut allergy is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis1. The difficulty in avoiding peanuts, combined with the severity of allergic reactions, shows the need for effective treatment3.

“We are delighted that Palforzia® has received regulatory approval in the U.S. for toddlers as there is a high unmet medical need for this age group and we are confident that this indication extension will alleviate the burden of peanut allergy for younger patients and their families,” says Elena Rizova, MD, PHD, Chief Medical Officer of Stallergenes Greer.

The FDA approval in toddlers is based on data from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023. The study evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years old, meeting all its primary and secondary efficacy endpoints and demonstrating a favourable safety profile.

Stallergenes Greer acquired the rights to Palforzia® in September 2023. As part of our ongoing commitment to delivering innovative solutions in allergen immunotherapy, our focus in the U.S has been on establishing a specialised Food Allergy business unit and transitioning the product into our AIT portfolio.

ABOUT PALFORZIA®

Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients. The treatment is approved for use in patients with a confirmed diagnosis of peanut allergy and in conjunction with a peanut-avoidant diet. Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

Palforzia® is approved by the U.S. Food and Drug Administration (FDA) for ages 1-17 years and for ages 4-17 years by the European Medicine Agency (EMA), by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland. Pediatric indication extension submissions are currently under review by the EMA and Swissmedic.

ABOUT POSEIDON PHASE 3 STUDY

POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, clinicaltrials.gov number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years of age in North America and Europe.

The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested Palforzia® to Stallergenes Greer in September 2023.

Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge.

In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of Palforzia® or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit double-blind, placebo-controlled food challenge (DBPCFC).

ABOUT STALLERGENES GREER INTERNATIONAL AG

Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory, food and venom allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.

1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/ Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.

Palforzia®: © 2023, Société des Produits Nestlé S.A. or its affiliates

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730211334/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Titan Telecoms deploys 800G flexible spectrum between Sydney and Melbourne with Adtran’s FSP 3000 TeraFlex™15.1.2025 14:15:00 CET | Press release

News summary: Resilient, high-speed connectivity is needed across Southeast Australia to support enterprise cloud services and data-intensive applications Multi-vendor network delivers high-capacity adaptive bandwidth over a long-haul link using Adtran terminal and Ciena OLS Dynamic spectrum allocation and optimized fiber utilization enable cost-effective, high-speed data transport across long distances Adtran announced today that Titan Telecomsis using its FSP 3000 TeraFlex™ CoreChannel™ technology to transport 800Gbit/s flexible spectrum services over a 963km backbone link between Sydney and Melbourne. This multi-vendor network addresses high-capacity connectivity needs by enabling commercial spectrum service offerings across Southeast Australia. The new service utilizes Adtran’s FSP 3000 TeraFlex™ CoreChannel™ optical terminal to enable dynamic bandwidth allocation and optimized fiber utilization. Its success sets a new standard for flexible spectrum transport and future high-capaci

The smarter E Europe: Bidirectional Charging Saves Billions15.1.2025 14:00:00 CET | Press release

Electric cars equipped with bidirectional charging technology can store electricity and feed it back into the grid when needed. A new study by Transport & Environment (T&E) shows that this could save billions by optimizing the use of generation capacity, reducing curtailment, and lowering fuel consumption. Bidirectional charging (BiDi) could thus achieve a technological and economic breakthrough in Europe but it requires clear regulatory framework conditions. Without these, the potential will remain untapped. In response to these developments, Europe’s largest alliance of energy industry exhibitions, The smarter E Europe, is dedicating a special exhibit to highlight the opportunities and challenges for the mobility and energy industries. The event will take place from May 7–9, 2025, at Messe München. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115069203/en/ The interplay of mobility and renewable energy: The smarter E

Arthur D. Little Blue Shift Report Explores Transformative Impact of AI on Research, Development, and Innovation15.1.2025 13:00:00 CET | Press release

AI has started to power all steps of research, development, and innovation (R&D&I), including those that require creativity, working alongside and augmenting humans, with its use increasing rapidly. However, while it is already delivering major productivity gains in specific areas or sectors its widespread integration into R&D&I processes is still relatively immature, and it faces a range of challenges around technology, economics, regulation, and societal acceptability. Irrespective of these challenges, six no-regret strategic actions should be undertaken today. These are the headline findings of Eureka! on Steroids: AI-driven research, development, and innovation, a new report published today byArthur D. Little (ADL)’s Blue Shift Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115868503/en/ In this new study, Arthur D. Little explores the current state of AI in research, development, and innovation. (Photo: Bu

Europastry and Blue Yonder Team Up To Strategically Drive Efficiency, Sustainability and Customer Satisfaction15.1.2025 10:00:00 CET | Press release

Global bakery leader implements Blue Yonder transportation management solutions supported by BlueGistics to optimize supply chain operations across Europe Delivering frozen bakery products presents several challenges that can impact the efficiency, profitability and sustainability of the supply chain. To address these challenges, Europastry, a world leader in the frozen bakery industry, has selected Blue Yonder’s transportation management solutions to evolve its supply processes and optimize its logistics operations. The transformational project was deployed by BlueGistics, a Blue Yonder partner and worldwide consulting company specializing in the implementation of Transportation Management Systems. With an ever-growing distribution network spanning more than 80 countries, Europastry sought to increase efficiency in its transportation processes, reduce costs, and continue delivering its wide range of bakery products efficiently. Blue Yonder’s transportation management solutions provide

Tax Systems Launches AI-powered, SaaS Solution for Global Pillar Two Compliance and Reporting15.1.2025 09:00:00 CET | Press release

Secure, scalable software that ensures organisations are prepared for the challenges of OECD Pillar Two rules now and in the future Tax Systems, the global multi-tax compliance SaaS provider, has today announced the availability of Pillar2, an intuitive solution to de-risk and simplify compliance with the OECD’s global Pillar Two tax rules. Designed for organisations operating across multiple jurisdictions - Pillar2 will save businesses valuable time and reduce the risk of errors, so they can cost effectively operationalise Pillar Two reporting and comply with confidence. Pillar2 integrates seamlessly with the provisioning and country-by-country reporting applications on TaxSuite - Tax Systems’ modular platform for international tax compliance. This means organisations can upload information once and re-use it as a single source of truth for their tax compliance data - helping to ensure consistency and accuracy across the tax reporting cycle and strengthen tax control frameworks. The s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye